IO Biotech to Present at Upcoming Healthcare Conferences
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company dedicated to developing innovative immune-modulating therapeutic cancer vaccines based on the T-win platform, recently announced the upcoming participation of its senior management team in various investor conferences. These engagements will provide insights regarding the company's ongoing projects and future potential.
Details of the Conferences
At the Morgan Stanley 22nd Annual Global Healthcare Conference, taking place shortly, Dr. Mai-Britt Zocca, the CEO of IO Biotech, will participate in a fireside chat scheduled for September 4, 2024, at 5:35 pm ET. This conference represents a significant opportunity for IO Biotech to connect with potential investors and deliver a corporate update directly related to the ongoing developments in their therapeutic offerings.
H.C. Wainwright Conference Participation
Following that, at the H.C. Wainwright 26th Annual Global Investment Conference, Amy Sullivan, CFO of IO Biotech, is scheduled to present the company’s strategic initiatives on September 9, 2024, at 10:30 am ET. This presentation is intended to outline the progress of IO Biotech's pipeline and innovative approaches to cancer treatment.
Accessing the Webcast
A live webcast of these presentations will be available on IO Biotech's official website, offering a chance for interested parties to engage with the content remotely. Following the events, the recording will remain accessible for approximately 90 days, allowing for wider audience participation.
About IO102-IO103
IO102-IO103 is an experimental cancer vaccine designed to engage the immune system in combating both tumor cells and the immunosuppressive cells that impede effective immune responses within the tumor microenvironment (TME). This innovative therapy aims to boost T cell activation against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells, which are critical targets in cancer treatment.
Clinical Trials and Partnerships
The clinical trials for IO102-IO103 are currently at pivotal phases. The company is conducting a Phase 3 trial (NCT05155254) comparing the vaccine in combination with pembrolizumab against pembrolizumab alone in patients suffering from advanced melanoma. Additionally, they are engaging in a Phase 2 basket trial (NCT05077709) examining the efficacy as a first-line treatment for patients with a variety of solid tumors, alongside another Phase 2 study (NCT05280314) focused on neo-adjuvant/adjuvant treatments. These studies are sponsored by IO Biotech in collaboration with Merck, which is providing pembrolizumab for the trials.
About IO Biotech
IO Biotech is a forward-thinking clinical-stage biopharmaceutical firm focused on the development of immune-modulating cancer therapies. Their T-win platform offers a fresh perspective on cancer vaccine technology, harnessing the body’s immune response to address tumor-supportive cells. IO Biotech is currently progressing with its lead candidate, IO102-IO103, through clinical trials while also evaluating additional candidates at the preclinical stage.
Based on their promising data from Phase 1/2 trials for metastatic melanoma, IO102-IO103 has received breakthrough therapy designation from the US Food and Drug Administration, enhancing its potential in the oncology landscape. IO Biotech operates globally, with headquarters in Copenhagen and a prominent presence in New York.
Contact Information
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
Email: mci@iobiotech.com
Media
Julie Funesti
Salutem
917-498-1967
Email: Julie.Funesti@salutemcomms.com
Frequently Asked Questions
What is the focus of IO Biotech?
IO Biotech specializes in developing immune-modulating therapeutic cancer vaccines.
When will IO Biotech present at investor conferences?
IO Biotech will participate in the Morgan Stanley Conference on September 4, 2024, and the H.C. Wainwright Conference on September 9, 2024.
How can I access the presentations from IO Biotech?
The webcast of the presentations will be available on IO Biotech's website for 90 days following the events.
What is IO102-IO103?
IO102-IO103 is an investigational therapeutic cancer vaccine targeting tumor cells and immune-suppressive cells in the tumor microenvironment.
Who are IO Biotech's collaborators for clinical trials?
IO Biotech conducts its clinical trials in collaboration with Merck, which supplies pembrolizumab for ongoing studies.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Murphy Oil Corporation Unveils Early Tender Results for Debt
- Snap-on Incorporated Plans to Broadcast Third Quarter Results
- Gold Reserve's Update Signals Progress in Sale Proceedings
- Orbis Medicines Unveils R&D Expansion at Copenhagen Hub
- Exciting Gold Intersections Reported by Kobo Resources' Drilling
- Voter Perspectives on Crypto Policies: Trump vs. Harris
- Exciting New Store Launch of Red White & Blue Thrift Store
- Exploring Defensive Stocks with Exceptional Dividend Yields
- Unlocking New Exploration Potential: Nevada King Gold Corp.
- Constellation Brands Shows Strong Growth in Fiscal Q2 Results
Recent Articles
- Varonis Systems to Showcase Innovations at Investor Conference
- Flywire Corporation to Participate in Key Investor Conferences
- ORIC Pharmaceuticals Announces Participation in Investor Events
- Aura Biosciences Presents Phase 2 Data on Bel-sar Treatment
- Avista Announces Leadership Transition as CEO Dennis Vermillion Retires
- Structure Therapeutics Engages with Investors at Key Conferences
- Calavo Growers Inc. to Announce Q3 Financial Results
- DSS, Inc. Appoints Jason Grady as Interim CEO
- Shuttle Pharmaceuticals Faces Nasdaq Listing Non-Compliance
- Pineapple Energy Reports on Recent Financial Performance Insights
- DeNube Launches Revolutionary Decentralized GPU Cloud Network
- Massey Ferguson 9S Series Tractor: A Game Changer for Farmers
- Nvidia Earnings: An Underpriced Risk for Investors
- Oroco Resource Corp. PEA Update Webinar and Report Filing
- McEwen Mining Partners for 100% Renewable Energy in Copper Project
- Tech Stocks Struggle as Nvidia Earnings Approach
- Harvard Apparatus Secures $5 Million for Clinical Advancements
- Understanding Medical Properties Trust's Dividend Cut
- Understanding Roth IRAs and the Social Security Tax
- Understanding the Recent Decline of Icahn Enterprises
- Industrial Food Blanchers Market to Reach USD 574 Billion
- Brady Corporation to Host Earnings Conference Call
- Union Claims Against Chipotle Highlight Labor Rights Issues
- Nvidia Prepares for Second Quarter Earnings Report
- Ergodyne's Advanced Tool Tethering Solutions Announced
- Associa Canada Achieves Great Place To Work Certification
- Kingswood Capital Partners Closes $8 Million IPO for WORK MedTech
- Pixalate's Q2 2024 Fraudulent CTV Bundle IDs Report
- Aesthetic Medicine Market Growth to USD 205.32 Billion
- MasHash Unveils Revolutionary Cloud Mining Platform
- Mowi ASA (OSE: MOWI) Announces Senior Executive Share Options
- PDD Holdings Faces Challenges Amidst Growth Fluctuations
- V3V Ventures Bolsters Blockchain Innovation with U2U and CrossCurve
- WORK Medical Technology Group LTD Completes IPO Successfully
- Jack Dorsey's Vision for Block as a Crypto Leader
- Key Insights on Upcoming Stock Splits This Week
- Shell plc Announces Share Buy-Back Transactions
- Dermal Fillers Market Growth and Trends
- Growth Prospects of the Wire Cutting Machine Market
- BioNexus Gene Lab Invests RM 1 Million in AI Healthcare Tech
- Genmab to Share Insights at Global Healthcare Conference
- Mixed Market Performance as Investors Eye Nvidia Earnings
- Associa Achieves Prestigious Great Place to Work Standard
- Automotive Auxiliary Lamps Market Growth Forecasts
- Intragastric Balloons Market Growth Insights and Trends
- Immunoassay Market Set to Thrive with 5.8% CAGR Growth
- NBME Launches Fee Assistance Program for Medical Students
- Blank Rome Expands Boston Office with Fraser Collin
- Endeavors Unlimited and Morgan’s MAC Partner for Disability Support
- Wreaths Across America Encourages Nationwide Flag Waving